BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26208992)

  • 41. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.
    Chen-Liang TH; Martin-Santos T; Jerez A; Senent L; Orero MT; Remigia MJ; Muiña B; Romera M; Fernandez-Muñoz H; Raya JM; Fernandez-Gonzalez M; Lancharro A; Villegas C; Carlos Herrera J; Frutos L; Luis Navarro J; Uña J; Igua C; Sanchez-Vaño R; Cozar Mdel P; Contreras J; Sanchez-Blanco JJ; Perez-Ceballos E; Ortuño FJ
    Am J Hematol; 2015 Aug; 90(8):686-90. PubMed ID: 25925613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
    Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiparametric analysis of bone marrow in cancer patients using simultaneous PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric data.
    Schraml C; Schmid M; Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF
    J Magn Reson Imaging; 2015 Oct; 42(4):1048-56. PubMed ID: 25683203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of intravascular large B-cell lymphoma in the left adrenal and another tumor in the right adrenal detected by (18)F-FDG PET/CT.
    Li W; Lin W; Ma C; Zhang L; Sun H
    Hell J Nucl Med; 2016; 19(1):57-9. PubMed ID: 26929945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma.
    Littooij AS; Kwee TC; Barber I; Granata C; de Keizer B; Beek FJ; Hobbelink MG; Fijnheer R; Stoker J; Nievelstein RA
    Acta Radiol; 2016 Feb; 57(2):142-51. PubMed ID: 25681490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
    Zhang Q; Tian T; Wang L; Qiu H; Li D
    Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging by ¹⁸F-FDG PET/CT of diffuse large B-cell lymphoma with cellulitis.
    Zhang Y; Li B; Cai L; Shi H; Hou J
    Hell J Nucl Med; 2015; 18(3):271-2. PubMed ID: 26574700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.
    Ahlawat S; Baig A; Blakeley JO; Jacobs MA; Fayad LM
    J Magn Reson Imaging; 2016 Oct; 44(4):794-803. PubMed ID: 26991037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.
    Wang LJ; Wu HB; Wang M; Han YJ; Li HS; Zhou WL; Wang QS
    Eur J Radiol; 2015 Nov; 84(11):2275-9. PubMed ID: 26388466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined early dynamic (18)F-FDG PET/CT and conventional whole-body (18)F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma.
    Wang SB; Wu HB; Wang QS; Zhou WL; Tian Y; Li HS; Ji YH; Lv L
    Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):324-30. PubMed ID: 25487755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging.
    Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S
    Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of serial multi-parametric functional MRI (diffusion-weighted imaging and R2*) with (18)F-FDG-PET in patients with head and neck cancer treated with radiation therapy.
    Min M; Lee MT; Lin P; Holloway L; Wijesekera Dj; Gooneratne D; Rai R; Xuan W; Fowler A; Forstner D; Liney G
    Br J Radiol; 2016; 89(1058):20150530. PubMed ID: 26648404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
    Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated whole-body PET/MR: Correlation with pathological prognostic factors.
    Shih IL; Yen RF; Chen CA; Chen BB; Wei SY; Chang WC; Sheu BC; Cheng WF; Tseng YH; Chen XJ; Chen CH; Wei LH; Chiang YC; Torng PL; Yen ML; Shih TT
    J Magn Reson Imaging; 2015 Dec; 42(6):1723-32. PubMed ID: 25919115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.